Acrylic Acid And Derivatives Patents (Class 424/487)
-
Publication number: 20110238036Abstract: An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles.Type: ApplicationFiled: December 22, 2010Publication date: September 29, 2011Applicant: pSivida US, Inc.Inventor: Paul Ashton
-
Patent number: 8025902Abstract: Provided are compositions comprising a low molecular weight, non-crosslinked, linear acrylic copolymer and at least one surfactant selected from the group consisting of anionic surfactants, amphoteric surfactants, and combinations of two or more thereof, and methods of using such compositions.Type: GrantFiled: August 18, 2010Date of Patent: September 27, 2011Assignee: Johnson & Johnson Consumer Companies, Inc.Inventors: Joseph J. Librizzi, Russel M. Walters, Michael Fevola, Krishnan Tamareselvy
-
Publication number: 20110229572Abstract: A composition comprising microspheres of a polymer matrix, having two different pharmaceutical actives having complementary, usually synergistic, activity in killing cells. The compositions have particular utility for treating tumours. Useful combinations are doxorubicin with rapamycin, irinotecan with ibuprofen, ibuprofen with doxorubicin and irinotecan with doxorubicin. The polymer matrix is preferably a crosslinked polyvinyl alcohol. The drugs may be included in the same microsphere, or microspheres each with an individual pharmaceutical agent may be mixed together. The microspheres are preferably used in chemoembolisation of tumours.Type: ApplicationFiled: August 18, 2008Publication date: September 22, 2011Applicant: BIOCOMPATIBLES UK LimitedInventors: Andrew Lennard Lewis, Richard Edward John Forster, Mroa Voctoria Gonzalez-Fajardo, Yiqing Tang, Andrew Willam LLoyd, Gary John Phillips
-
Publication number: 20110230816Abstract: The present disclosure provides hydrogels that are suitable for drug delivery. In embodiments, hydrogels of the present disclosure may be used for transdermal delivery of bioactive agents, including drugs. The hydrogels of the present disclosure may also be useful as conductive compositions for use with electrodes.Type: ApplicationFiled: August 31, 2010Publication date: September 22, 2011Applicant: TYCO HEALTHCARE GROUP LPInventor: Warren Copp-Howland
-
Publication number: 20110223230Abstract: A polymeric prodrug composition including a hydrogel, a biologically active moiety and a reversible prodrug linker. The prodrug linker covalently links the hydrogel and the biologically active moiety at a position and the hydrogel has a plurality of pores with openings on its surface. The diameter of the pores is larger than that of the biologically active moiety at least at all points of the pore between at least one of the openings and the position of the biologically active moiety.Type: ApplicationFiled: May 19, 2011Publication date: September 15, 2011Applicant: ASCENDIS PHARMA A/SInventors: Ulrich Hersel, Harald Rau, Robert Schnepf, Dirk Vetter, Thomas Wegge
-
Patent number: 8017566Abstract: A mild, substantially isotropic skin cleansing solution was found to be able to suspend insoluble components and provide copious amounts of lather. The cleanser is formulated with synthetic anionic surfactants and a specific ratio of carboxylic acid(s) to hydrophobically modified cross-linked acrylate copolymer(s). The carboxylic acid and acrylate polymer combination were found to provide a synergistic effect on zero shear viscosity at 25 C in a specific pH and copolymer/acid concentration ratio range.Type: GrantFiled: November 13, 2009Date of Patent: September 13, 2011Assignee: Conopco, Inc.Inventors: Anat Shiloach, Suzanne Lynn Gencarelli, Sirisha Muppidi, Michael A. Rahn, Rosa Mercedes Paredes
-
Publication number: 20110206769Abstract: Provided are methods for reducing the excipient load of pharmaceutical formulations containing 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide as the active pharmaceutical ingredient, and compositions related thereto. In particular, provided is a pharmaceutical product comprising 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide and a stabilizer admixed throughout a solid-form unilamellar matrix, wherein the ratio of 3-fluoro-7-(2,2,2-trifluoroethoxy)phenoxathiin 10,10-dioxide to stabilizer ranges from about 2:3 to about 1:10, and related methods of forming the pharmaceutical product.Type: ApplicationFiled: August 20, 2010Publication date: August 25, 2011Applicant: CeNeRx BioPharma, Inc.Inventors: Andrew Chen, Hailiang Chen, James Cecil Free, Majid Keshtmand, Mohammed Abdul Rahman, Sally A. Look
-
Patent number: 8003121Abstract: System of implant components containing active agents, wherein each component is intended to function as an additive for an implant material produced with a powdery or finely granulated starting material and/or active agents and additives. Each component is powdery or finely granulated and includes at least one powdery or finely granulated active agent or additive having a higher dosage than the desired concentration for the application. The components themselves are made of a powdery or finely granulated starting material for the implant material, as well as of the active agent or additive. The active agents can be chemotherapeutical agents, such as antibiotics, whereas the additives can be x-ray contrast materials and/or or additives that alter the physical properties of the starting material, such as its elasticity or viscosity.Type: GrantFiled: August 1, 2000Date of Patent: August 23, 2011Assignee: aap Biomaterials GmbH & Co. KGInventors: Elvira Dingeldein, Helmut Wahlig, Jörg Bauer, Edgar Wüst, Christoph Sattig
-
Publication number: 20110200675Abstract: Drug delivery vehicles that release one or more drugs, e.g., an opioid antagonist and/or an opioid, in response to changes in the chemistry of body fluids, specifically in response to changes in the partial pressure of CO2 in the environment of the hydrogel are described. The drug delivery vehicles include hydrogels that swell or shrink in response to changes in the partial pressure of CO2 in their environment, thus regulating release of an entrapped drug.Type: ApplicationFiled: July 28, 2010Publication date: August 18, 2011Applicant: UNIVERSITY OF MASSACHUSETTSInventor: Sankaran Thayumanavan
-
Systems and methods that kill infectious agents (bacteria) without the use of a systemic anti-biotic
Publication number: 20110200655Abstract: A medical product is provided that is selected from at least one of, nasal cannulas, oxygen masks, wound dressings, bandages, band aids, catheters, endotrachial tubes, condoms, surgical and other gloves, sheaths for endoscopy probes, and medical products that physically touch the body. A coating is included with at least one of, a non-antibiotic, antimicrobial and/or antiviral substance that prevents further local, non-systemic, colonization of infections.Type: ApplicationFiled: February 16, 2011Publication date: August 18, 2011Inventors: Michael Darryl Black, Anita Margarette Chambers -
Patent number: 7998574Abstract: A method is disclosed of detecting a bioelectrical signal from a subject. The method includes the steps of applying a composite material to a subject wherein the composite material includes a polymeric material and a polar material that is substantially dispersed within the polymeric material; coupling monitoring equipment to the second side of the composite material; permitting the polar material within the polymeric material to respond to the bioelectrical signal within the subject; and detecting a responsive electrical signal from the composite material that is representative of the bioelectrical signal. The polar material exhibits molecular compatibility with the polymeric material such that the polar material neither blooms to a surface of the polymeric material nor crystallizes within the polymeric material, and the composite material has a first side for contacting the subject and a second side.Type: GrantFiled: December 14, 2010Date of Patent: August 16, 2011Assignee: FLEXcon Company Inc.Inventors: Daniel P. Segall, Iris E. Hilton, Melissa E. Szymanski, John R. Pennace
-
Patent number: 7993654Abstract: A self-adhesive polymer matrix which comprises a polymer that forms a gel in water, water, a sea algae extract, and a monohydric or polyhydric alcohol.Type: GrantFiled: September 22, 2010Date of Patent: August 9, 2011Assignee: Beiersdorf AGInventors: Karl-Heinz Woeller, Thorsten Berg, Inge Kruse, Rainer Wolber
-
Patent number: 7988992Abstract: The present invention features modified superporous hydrogels (SPHs) and methods for their formation. The SPHs of the present invention are prepared by careful selection of the hydrophobic/hydrophilic reactive ingredients and by harmonizing the foaming and polymerization reactions, which results in the formation of SPHs having a homogeneous structure and favorable physical and mechanical properties, including swelling, strength, ruggedness, and resiliency. The SPHs of the present invention are particularly useful when employed in very harsh swelling environments, such as the low pH environment of the gastric fluid of the stomach, for extended periods of time.Type: GrantFiled: July 6, 2007Date of Patent: August 2, 2011Assignee: KOS Life Sciences Abbott LaboratoriesInventors: Hossein Omidian, Jose G. Rocca
-
Publication number: 20110182968Abstract: The present invention provides materials that have high glucose and oxygen permeability, strength, water content, and resistance to protein adsorption. The materials include an interpenetrating polymer network (IPN) hydrogel that is coated with biomolecules. The IPN hydrogels include two interpenetrating polymer networks. The first polymer network is based on a hydrophilic telechelic macromonomer. The second polymer network is based on a hydrophilic monomer. The hydrophilic monomer is polymerized and cross-linked to form the second polymer network in the presence of the first polymer network. In a preferred embodiment, the hydrophilic telechelic macromonomer is PEG-diacrylamide, PEG-diacrylate or PEG-dimethacrylate and the hydrophilic monomer is an acrylic-based monomer. Any biomolecules may be linked to the IPN hydrogels, but are preferably biomolecules that support the growth of cornea-derived cells. The material is designed to serve as a corneal prosthesis.Type: ApplicationFiled: December 20, 2010Publication date: July 28, 2011Inventors: David Myung, Christopher N. Ta, Curtis W. Frank, Won-Gun Koh, Jaan Noolandi, Laura Hartmann
-
Publication number: 20110171308Abstract: A pH-sensitive solid pharmaceutical composition for oral formulation and preparation method thereof is provided. The solid pharmaceutical composition contains a pharmaceutical active ingredient, a nano-matrix carrier and a pH-sensitive polymer material.Type: ApplicationFiled: September 1, 2008Publication date: July 14, 2011Inventors: Qiang Zhang, Jiancheng Wang, Yulan Guo, Xuan Zhang, Zenggrong Jia, Ping Lin, Jinyang Zhang, Jie Zhang
-
Publication number: 20110171309Abstract: Provided herein are systems, methods, and compositions for composite nanoparticle hydrogel networks and systems responsive to a first temperature.Type: ApplicationFiled: March 25, 2009Publication date: July 14, 2011Applicant: Board of Regents, The University of Texas SystemInventors: Kytai Troung Nguyen, Prsnesh B. Aswath, Abhimanyo R. Sabnis, Aniket S. Wadajkar
-
Patent number: 7972589Abstract: The present invention relates to a hair fixative film, which contains a natural and/or synthetic polymer as the main component and a method of applying said film to hair. Such film is useful in maintaining a desired look and style of hair. Furthermore, the film is beneficial because it enables the combination of ingredients that are incompatible in other application forms.Type: GrantFiled: May 17, 2004Date of Patent: July 5, 2011Assignee: Akzo Nobel N.V.Inventors: John C. Leighton, Michael T. Philbin
-
Publication number: 20110150993Abstract: The disclosure is directed to fine particle croscarmellose and its use in various compositions such as solid dosage forms. More specifically, the present disclosure relates to fine particle croscarmellose having a median particle size of 5 ?m to 36 ?m and a volume mean diameter of 40 ?m or less. The specific surface area is typically 0.3 m2/g or more. The fine particle croscarmellose is useful as a disintegrant.Type: ApplicationFiled: December 16, 2010Publication date: June 23, 2011Applicant: FMC CORPORATIONInventor: Yeli Zhang
-
Publication number: 20110151006Abstract: The present invention relates to a hydrogel comprising a polymer, a first polypeptide and a polypeptide binding partner, wherein the polypeptide binding partner is a second polypeptide, a nucleic acid or a small molecule, and wherein the interaction between the first polypeptide and the polypeptide binding partner stabilizes the hydrogel and is modulated by the addition of a modulating compound. A drug may be physically entrapped in the hydrogel, bound to the polymer forming the hydrogel structure, or bound to the first polypeptide or the polypeptide binding partner, and then be set free on addition of the modulating compound. Such a hydrogel comprising a drug may be injected into a patient, and drug release modulated by orally administering the modulating compound.Type: ApplicationFiled: June 5, 2009Publication date: June 23, 2011Inventors: Wilfried Weber, Martin Fussenegger, Ronald Schoenmakers
-
Publication number: 20110150994Abstract: The invention is directed to the use of an extended release tablet formulation for pramipexole.Type: ApplicationFiled: February 28, 2011Publication date: June 23, 2011Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Thomas FRIEDL, Wolfram EISENREICH
-
Publication number: 20110135732Abstract: The present invention is directed to pharmaceutical compositions, and method for preparing pharmaceutical compositions, comprising a cross-linked matrix physically entrapping at least one therapeutic agent. The matrix may comprise one or more phases in addition to an aqueous phase, such as a solid and/or oil phase. The matrix of the invention has at least one controlled release in-vivo kinetic profile, and may have additional profiles for the same agent. The matrix may also comprise more than one therapeutic agent, and each additional therapeutic agent may have one or more controlled release in-vivo kinetic profile.Type: ApplicationFiled: November 22, 2010Publication date: June 9, 2011Applicant: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEYInventors: Stanley Stein, Bo Qiu, Patrick J. Sinko
-
Publication number: 20110129535Abstract: Described are transdermal drug delivery systems for the transdermal administration of testosterone, comprising a polymer matrix and testosterone. Methods of making and using such systems also are described.Type: ApplicationFiled: November 23, 2010Publication date: June 2, 2011Inventor: Juan A. Mantelle
-
Patent number: 7951395Abstract: The invention relates to a dermal for aminolaevulinic acid, wherein a self-adhesive matrix system is used containing crystalline aminolaevulinic acids.Type: GrantFiled: July 13, 2001Date of Patent: May 31, 2011Assignee: Photonamic GmbH & Co. KGInventors: Geoffrey Lee, Rolf-Markus Szeimies
-
Patent number: 7943174Abstract: A solid oral controlled-release oral dosage form of hydrocodone is disclosed. The dosage form comprising an analgesically effective amount of hydrocodone or a pharmaceutically acceptable salt thereof, and a sufficient amount of a controlled release material to render the dosage form suitable for twice-a-day administration to a human patient, the dosage form providing a C12/Cmax ratio of 0.55 to 0.85, said dosage form providing a therapeutic effect for at least about 12 hours.Type: GrantFiled: June 9, 2004Date of Patent: May 17, 2011Assignee: Purdue Pharma L.P.Inventors: Benjamin Oshlack, Hua-Pin Huang, John Masselink, Alfred P. Tonelli
-
Publication number: 20110111010Abstract: The present invention is directed to the use of an agent selected from ethyl alcohol, isopropyl alcohol or a mixture thereof and a topically acceptable polymeric carrier in the preparation of a composition for the treatment of burns.Type: ApplicationFiled: July 7, 2010Publication date: May 12, 2011Applicant: Yissum, Research Development Company of the Hebrew University of Jerusalem Ltd.Inventor: Elka Touitou
-
Publication number: 20110111034Abstract: The present invention relates to the covalent binding of a hydrogel to an extracellular matrix (ECM). The integration of the hydrogel with the tissue is superior to that in previous techniques. Moreover, unlike previous techniques, the present invention does not require a photoinitiator. Potential therapeutic applications include tissue repair and delivery of drugs or cells. The ECM is first exposed, then treated with a priming agent. Then a polymerizable agent is added and crosslinked to the ECM. Two primary embodiments of methods are disclosed. In the first, the priming agent is an oxidizer which creates tyrosyl radicals in the ECM, which are then bound by acrylate groups in the polymerizable agent. In the second, the priming agent contains aldehydes which bind amino groups in the ECM.Type: ApplicationFiled: January 18, 2011Publication date: May 12, 2011Inventors: Dong-an Wang, Anthony Ratcliffe, Jennifer H. Elisseeff
-
Publication number: 20110111033Abstract: A novel hydrogel system is provided. The hydrogel system comprises a biocompatible hydrogel core having dispersed therein a covalently crosslinked polymer matrix. The hydrogel system is useful per se or as an encapsulation system.Type: ApplicationFiled: April 9, 2009Publication date: May 12, 2011Inventors: Harald Stover, Nicholas Burke, M.A. Jafar Mazumder, Feng Shen, Murray Potter
-
Publication number: 20110104273Abstract: Gastric retentive dosage forms for both immediate and extended release of phenylephrine are described which allow once- or twice-daily dosing. Methods of treatment using the dosage forms and methods of making the dosage forms are also described.Type: ApplicationFiled: November 5, 2010Publication date: May 5, 2011Applicant: DEPOMED, INC.Inventor: Sui Yuen Eddie Hou
-
Publication number: 20110104283Abstract: A composition and method for treating a bone condition of an animal. The composition includes a nanoformulation of active ingredients. The active ingredients include Lepidium Sativum or other Lepidium extracts, calcium, vitamin D, and antioxidants. The method for treating a bone condition includes introducing the composition into the animal.Type: ApplicationFiled: October 27, 2010Publication date: May 5, 2011Inventors: Shaker A. Mousa, Mohammed H. Qari, Mohammed S. Ardawi
-
Patent number: 7932258Abstract: The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by weight of (meth)acrylate monomers with an anionic group, at least 4 percent of which are neutralized by means of a base, for producing a medicament that is provided with an active substance-containing core and is coated with the partially neutralized, anionic (meth)acrylate copolymer. The medicament releases at least 30 percent of the active substance contained therein in 30 minutes at a pH at which the active substance is sufficiently soluble and stable and at which the corresponding medicament that is coated with the non-neutralized anionic (meth)acrylate polymer releases less than 10 percent of the active substance contained therein.Type: GrantFiled: April 5, 2006Date of Patent: April 26, 2011Assignee: Evonik Roehm GmbHInventors: Hans-Ulrich Petereit, Manfred Assmus
-
Publication number: 20110091555Abstract: A hydrophilic matrix is disclosed which comprises: a) at least one polyacrylic acid derivative in preferred amounts of 0.5-40%, b) at least one cellulose ether in preferred amounts of 30-90% and c) at least one disintegrant in preferred amounts of 2-50%, with respect to the weight of the matrix. This matrix is used in combination with at least one pharmaceutically acceptable active principle for manufacturing solid bioadhesive controlled release formulations for the treatment of vaginal disorders, such as vulvovaginal candidiasis, bacterial vaginosis or trichomoniasis. According to a preferred embodiment, the matrix is used in amounts of about 5-60% and the active principle in amounts of about 2-70%, with respect to the weight of the formulation.Type: ApplicationFiled: July 21, 2007Publication date: April 21, 2011Applicant: POLICHEM S.A.Inventors: Stefano De Luigi Bruschi, Federico Mailland
-
Publication number: 20110086102Abstract: The present invention provides delayed release pharmaceutical compositions comprising an active pharmaceutical ingredient, e.g. mycophenolate sodium, and an enteric polymer, and methods for preparing the same. Preferably, the pharmaceutical compositions do not contain a coating.Type: ApplicationFiled: October 13, 2009Publication date: April 14, 2011Applicant: Teva Pharmaceutical Industries Ltd.Inventors: David Isaac SILVER, Julia Hrakovsky, Roey Solomonovich, Dafna Arieli
-
Patent number: 7918897Abstract: Biocompatible synthetic or natural scaffolds are provided for the reconstruction, repair, augmentation or replacement of organs or tissue structures in a patient in need of such treatment. The scaffolds are shaped to conform to at least a part of the organ or tissue structure and may be seeded with one or more cell populations. Inserts, receptacles and ports are also provided for the attachment of tubular vessels to the neo-organ scaffolds. The seeded scaffolds are implanted into the patient at the site in need of treatment to form an organized organ or tissue structure. The scaffolds may be used to form organs or tissues, such as bladders, urethras, valves, and blood vessels.Type: GrantFiled: February 12, 2007Date of Patent: April 5, 2011Assignee: Tengion, Inc.Inventors: Timothy A. Bertram, Andrew Bruce, Deepak Jain, Manuel J. Jayo, John W. Ludlow, Darell McCoy, Richard Payne, Namrata D. Sangha
-
Patent number: 7910120Abstract: A cosmetic composition where a linear, block ethylenic copolymer is dissolved in a physiologically acceptable medium, wherein the linear, block ethylenic copolymer improves the hold of hair lacquer, increases the adhesion of a nail varnish and improves the hold and adhesion of makeup.Type: GrantFiled: September 7, 2006Date of Patent: March 22, 2011Assignee: L'OrealInventors: Nathalie Mougin, Bertrand Lion
-
Patent number: 7910135Abstract: The present invention relates to a method of forming shape-retentive and shape-conforming aggregate wound dressings and biomaterials composed of gel nanoparticles and wound or bodily fluid in which the aggregates are held together by non-covalent bond physical forces such as, without limitation, hydrophobic-hydrophilic interactions and hydrogen bonds. The method comprises introducing a dry powder of gel nanoparticles to a wound site in which the nanoparticles absorb some of the blood or wound exudate and coalesce in situ into the claimed shape-retentive aggregate dressing. The method also comprises introducing the dry nanoparticle powder in or on a wet bodily tissue in vivo to form the claimed shape-retentive biomaterial. In addition, the method also comprises incorporating biomedical agents to produce medicated aggregate dressings or biomaterials for a variety of medical applications. This invention also relates to uses of the method of formation of the shape-retentive aggregates of gel nanoparticles.Type: GrantFiled: October 13, 2006Date of Patent: March 22, 2011Assignee: ULURU Inc.Inventors: John St. John, Daniel G. Moro
-
Patent number: 7906126Abstract: A cosmetic composition of a linear, block ethylenic copolymer dissolved in a physiologically acceptable medium where the linear, block ethylenic copolymer includes at least two blocks having different glass transition temperatures, Tg; and one of the blocks is a copolymer of different monomers chosen from acrylates and/or methacrylates.Type: GrantFiled: September 7, 2006Date of Patent: March 15, 2011Assignee: L'OrealInventors: Nathalie Mougin, Bertrand Lion
-
Publication number: 20110059176Abstract: The present invention provides a tissue adhesion prevention material preparable at an affected area at the time of surgical procedure by producing a three-dimensional polymeric structure having a flexible structure and high solute permeability in a medium comprising water as the main component under mild conditions appropriate for body tissue components (i.e., at ordinary temperature and pressure) without conducting a chemical reaction or employing a physical procedure such as heating or light or radiation irradiation. This makes it possible to provide a tissue adhesion prevention material and a joint contracture prevention materials, which can effectively prevent postoperative adhesion of a tissue in the affected area to the surrounding tissue and contracture of the movable part of a joint.Type: ApplicationFiled: November 14, 2008Publication date: March 10, 2011Applicant: THE UNIVERSITY OF TOKYOInventors: Toru Moro, Kozo Nakamura, Hiroshi Kawaguchi, Noriyuki Ishiyama, Kazuhiko Ishihara, Tomohiro Konno, Tadashi Ohyama, Mizuna Yoshikawa
-
Patent number: 7897195Abstract: Various embodiments of methods and devices for coating stents are described herein.Type: GrantFiled: June 15, 2007Date of Patent: March 1, 2011Assignee: Abbott Cardiovascular Systems Inc.Inventors: David Rego, Kurt Kilchenmann, Sang joon Park, Mark Haight, Anthony S. Andreacchi, Yung-Ming Chen, Arnoldo M. Currlin, Antonio Garcia, Jason Van Sciver, Thomas David Esbeck, Bryan D. Glenn, Patrick A. Tuohy, Richard Baillargeon, Edward P. Garcia, Steven E. Lehner
-
Patent number: 7883720Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.Type: GrantFiled: July 7, 2004Date of Patent: February 8, 2011Assignee: Wisconsin Alumni Research FoundationInventors: David M. Lynn, Adam D. Miller
-
Publication number: 20110027369Abstract: The invention relates to a pharmaceutical composition in the form of a hydrogel that comprises a carboxylic acid diester, a C2-C4 alkyl alcohol, an active ingredient and a polymer matrix. The invention also relates to the use of a carboxylic acid diester as a transdermal permeation enhancer for an active ingredient in a pharmaceutical composition in the form of a hydrogel, whereby the composition comprises a polymer matrix and a C2-C4 alkyl alcohol. The invention also relates to a sweat-resistant composition in the form of a hydrogel, which comprises an acrylic polymer in combination with a cellulose derivative.Type: ApplicationFiled: August 18, 2010Publication date: February 3, 2011Inventor: Patrick FRANKE
-
Publication number: 20110027345Abstract: The present invention relates to a composition containing Rotigotine and the use thereof in the manufacture of a Rotigotine-containing transdermal patch, wherein said composition is based on a matrix mixture system formed from a combination of an acrylic pressure-sensitive adhesive with a silicone pressure-sensitive adhesive, and polyvinylpyrrolidone which are present in a particular weight ratio, wherein (1) the acrylic pressure-sensitive adhesive is present in an amount of about 1-25% by weight in the matrix mixture system, (2) the silicone pressure-sensitive adhesive is present in an amount of about 65-98% by weight in the matrix mixture system, and (3) the polyvinylpyrrolidone is present in an amount of about 1-10% by weight in the matrix mixture system, and comprises 1-40% of Rotigotine on the basis of the total weight of the composition. The present invention further relates to an improved transdermal patch containing Rotigotine comprising said composition.Type: ApplicationFiled: July 3, 2008Publication date: February 3, 2011Inventors: Shuming Wang, Huiyong Xue, Li Wang, Enhong Zhang, Hongjun Lian, Xiaoyan Shi, Guohua Chi, Yucheng Lu, Xiquan Liu, Li Song, Xuying Zhong, Hongguang Du
-
Publication number: 20110027172Abstract: The present invention provides a drug delivery system for delivery of an agent and a radiopharmaceutical agent. The drug delivery system may specifically target an organ, tissue, cells, extracellular matrix, or intracellular compartment. Typically, the drug delivery system is a particle. Pharmaceutical compositions comprising the inventive particles are also provided. The present invention provides methods of preparing and using the inventive particles and pharmaceutical compositions. The inventive particles are useful in treating and diagnosing a variety of diseases including cancer. The inventive particles are also useful in tracking particles in vivo.Type: ApplicationFiled: December 10, 2008Publication date: February 3, 2011Inventors: Zhuang Wang, Omid C. Farokhzad, Liangfang Zhang, Aleksandar Filip Radovic-Moreno, Frank X. Gu, Robert S. Langer
-
Publication number: 20110020444Abstract: We provide a pharmaceutical dosage form including an opioid antagonist surrounded by a controlled release matrix and an opioid agonist in a surrounding matrix.Type: ApplicationFiled: September 30, 2010Publication date: January 27, 2011Applicant: Endo Pharmaceuticals, Inc.Inventors: Huai-Hung Kao, Yadi Zeng, Michelle Howard-Sparks, Fai Jim
-
Patent number: 7875212Abstract: Embodiments of the present invention provide polymer matrix nanocomposites reinforced with nano-scale materials such as nanoparticles and carbon nanotubes and methods of fabricating. The nanomaterials are provided within relatively low weight fractions, for example in the range of approximately 0.01 to about 0.4% by weight and distributed within the matrix by a magnetic mixing procedure to provide substantially uniform reinforcement of the nanocomposites. Advantageously, these nanocomposites provide significantly enhanced tensile strength, strain to failure, and fracture toughness over corresponding neat matrices.Type: GrantFiled: February 9, 2010Date of Patent: January 25, 2011Assignee: University of HawaiiInventors: Mohammad Naghi Ghasemi Nejhad, Vinod P Veedu, Andrea Yuen, Davood Askari
-
Patent number: 7867611Abstract: A biomedical sensor is disclosed that includes a conductive material for coupling to monitoring equipment, and a composite. The composite includes a polymeric material and a polar material that is substantially dispersed within the polymeric material. The composite has a first side that is coupled to the conductive material and has a second side that is positionable with respect to a subject to be monitored. The polar material exhibits molecular compatibility with the polymeric material such that the polar material neither blooms to a surface of the polymeric material nor crystallizes within the polymeric material.Type: GrantFiled: March 31, 2010Date of Patent: January 11, 2011Assignee: FLEXcon Company, Inc.Inventors: Daniel P. Segall, Iris E. Hilton, Melissa E. Szymanski, John R. Pennace
-
Publication number: 20100323015Abstract: A modified release pharmaceutical formulation includes about 30-70% N-(2-amino-4-(fluorobenzylamino)-phenyl) carbamic acid ethyl ester (retigabine), or a pharmaceutically acceptable salt, solvate or hydrate thereof, about 5-30% of a drug delivery matrix including hydroxypropylmethylcellulose (HPMC), and an enteric polymer. The pharmaceutical formulation produces a sustained plasma concentration of retigabine following administration to a subject for 4-20 hours longer than the time required for in vitro release of 80% of retigabine. The plasma concentration vs. time profile of this formulation is substantially flat over an extended period lasting for about 4 hours to about 36 hours. A method of treating a disorder characterized by nervous system hyperexcitability includes administering to a subject an effective amount of these pharmaceutical formulations.Type: ApplicationFiled: January 20, 2010Publication date: December 23, 2010Inventor: Biljana Nadjsombati
-
Patent number: 7854924Abstract: The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising sodium-binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hypertension, chronic heart failure, end stage renal disease, liver cirrhosis, chronic renal insufficiency, fluid overload, or sodium overload.Type: GrantFiled: March 30, 2004Date of Patent: December 21, 2010Assignee: Relypsa, Inc.Inventors: Robert Alpern, Jerry Buysse, Han Ting Chang, Dominique Charmot, Michael James Cope, John Fordtran, Gerrit Klaerner, Eric Connor, Mingjun Liu, Futian Liu, Jun Shao
-
Publication number: 20100316722Abstract: Pharmaceutical form containing at least an active compound and a polymeric matrix, wherein said polymeric matrix comprises at least one polymer of cationic nature and at least one biodegradable polymer, process for the preparation thereof, pharmaceutical formulations comprising said pharmaceutical form, and their uses. The pharmaceutical form provides enhanced absorption of active compounds across the mucosa.Type: ApplicationFiled: May 13, 2010Publication date: December 16, 2010Applicant: LABORATORIOS FARMACEUTICOS ROVI S.A.Inventors: Iván LOPEZ-BELMONTE ENCINA, Ibon GUTIERRO ADURIZ, Philippe MAINCENT
-
Publication number: 20100291216Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: November 18, 2010Inventors: Jan-Erik Löfroth, Jonas Ödman
-
Publication number: 20100291217Abstract: The present invention relates to pharmaceutical compositions for sustained release comprising a water soluble salt of the HMG-CoA reductase inhibitor fluvastatin as active ingredient, said composition being selected from the group comprising matrix formulations, diffusion-controlled membrane coated formulations; and combinations thereof.Type: ApplicationFiled: June 8, 2010Publication date: November 18, 2010Inventors: Jan-Erik Löfroth, Jonas Ödman